View More Recent Stories
-
MBX Biosciences (MBX) Misses Q4 EPS by 47c
-
MBX Biosciences (MBX) Announces Additions to Leadership Team
-
MBX Biosciences (MBX) Announces Positive Phase 1 Topline Results for MBX 1416
-
MBX Biosciences (MBX) Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
(MBX) Misses Q3 EPS by 278c
-
JPMorgan Starts MBX Biosciences Inc (MBX) at Overweight
-
Jefferies Starts MBX Biosciences Inc (MBX) at Buy
-
Guggenheim Starts MBX Biosciences Inc (MBX) at Buy
-
Stifel Starts MBX Biosciences Inc (MBX) at Buy
-
MBX Biosciences (MBX) Opens At $23, IPO Priced At $16
-
MBX Biosciences (MBX) Files for 8.5M Share IPO at $14-$16/sh


